Bioavailability of oestradiol from the Alora® (0.1 mg/day) oestradiol matrix transdermal delivery system compared with Estraderm® (0.1 mg/day)

Journal of Obstetrics and Gynaecology

Volumn 18, Issue 6, 1998, Pages 575-580

  Bowen, Angela J ^a   John, V A ^b   Ramirez, Maria E ^b   Good, W R ^b  

^a Middleton Foundation   (United States)

^b TheraTarget Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; SULFATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031744033     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443619866408     Document Type: Article

References (11)

1. Balfour J. A. and Heel R. C. (1990) Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs, 40, 561-582.
2. Corson S. L. (1993) Clinical experience with System, a new transdermal form of hormone replacement therapy. International Journal of Fertility and Menopausal Studies, supplement 1, 38, 36-44.
3. Gordon S. F. (1995) Clinical experience with a seven-day cstradiol transdermal system for estrogen replacement therapy. American Journal of Obstetrics and Gynecology, 173, 998-1004.
4. Laufer L. R., DeFazio J. L., Lu J. K., Meldrum D. R., Eggena P., Sambhi M. P., Hephman J. M. and Judd H. L. (1983) Estrogen replacement therapy by transdermal cstradiol administration. American Journal of Obstetrics and Gynecology, 148, 533-540.
5. Marsh M. S. and Whitehead M. I. (1993) The practicalities of hormone replacement therapy. Bailliere's Clinical Endocrinology and Metabolism, 7, 183-202.
6. Miller-Bass K. and Adashi E. Y. (1990) Current and future prospects of transdermal estrogen replacement therapy. Fertility and Sterility, 53, 961-974.
7. Place V. A., Powers M., Darley P. E., Schenkel L. and Good W. R. (1985) A double-blind comparative study of Estraderm and Premarin in the amelioration of post-menopausal symptoms. American Journal of Obstetrics and Gynecology, 152, 1092-1099.
8. Smith R. D., Robinson D. E., Delignieres B., Albertson B. D., Tomai T. P., Zinaman M. J. and Simon J. A. (1991) Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system. Fertility and Sterility, 56, 1029-1033.
9. Speroff L. (1993) Menopause and hormone replacement therapy. Clinical Geriatric Medicine, 9, 33-55.
10. Studd J. W. W., McCarthy K., Zamblera D., Burger H. G., Silberberg S., Wren B., Dain M. P., Le-Lann and Vandepol C. (1995) Efficacy and tolerance of Menorest;® compared to Premarin® in the treatment of post-menopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas, 22, 105-114.
11. Wysowski D. K., Golden L., and Burke L. (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstetrics and Gynecology, 85, 6-10.